Transdermal hormone replacement therapy
Patent 5422119 Issued on June 6, 1995. Estimated Expiration Date: 
January 3, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
January 3, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesHormone preparation and method Hormone preparation and method Patent #: 5256421 InventorAssigneeApplicationNo. 177355 filed on 01/03/1994US Classes:424/449, Transdermal or percutaneous514/170Plural Compounds containing cyclopentanohydrophenanthrene ring systemsExaminersPrimary: Rose, Shep K.Attorney, Agent or FirmInternational ClassesA61K 031/565A61K 031/57 A61K 031/58 A61L 015/03 Foreign Application Priority Data1987-09-24 CAAbstractThe present invention provides a method of treating a female in need of hormone replacement therapy comprising transdermally administering to said female a series of alternating phases of from about one to about four days of estrogen dominant activity and phases of from about one to about four days of progestin dominant activity, with the estrogen dominant activity phase consisting of administering a transdermal estrogen substance alone or administering a transdermal estrogen substance and a transdermal progestin substance and the progestin dominant activity phase consisting of administering a transdermal progestin substance and a transdermal estrogen substance, the amount of progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity. | |
